Furthermore, the anti-HGF monoclonal antibody Ficlatuzumab demonstrated favourable tolerability in a phase Ib study when combined with the EGFR tyrosine kinase inhibitor gefitinib, and induced partial responses (PR) in a subset of patients, further underscoring its potential clinical value in the treatment of NSCLC (52). Here, EGFR is linked to non-small cell lung carcinoma.